An Evaluation of a Dynamic Web-Based Visualization of Community Immunity
- Conditions
- Vaccine-Preventable Diseases
- Interventions
- Behavioral: guardianmeaslesBehavioral: herdimmBehavioral: robertkochgenericBehavioral: sbsnewsgenericBehavioral: theotheredmundmeaslesBehavioral: publichealthagencycanadaflu
- Registration Number
- NCT04787913
- Lead Sponsor
- Laval University
- Brief Summary
This study is a PhD project conducted by Ms. Hina Hakim, supervised by Dr. Holly O. Witteman, PhD, and co-supervised Dr. Daniel Reinharz, professors and researchers at the Faculty of Medicine at Laval University. The purpose of this study is to evaluate the effects of visualization conveying the concept of community immunity or herd immunity on risk perception (towards individual, family, community and vulnerable people in communities) (primary outcome) and on emotions, attitudes, knowledge, and behavioural intentions (secondary outcomes).
- Detailed Description
Visualization is a powerful communication mechanism that uses pre-attentive processing to communicate large amounts of information rapidly in understandable and compelling ways (Healey and Enns 2012). A systematic review demonstrates that there are some interventions available for conveying the concept of community immunity, and very few evaluate interventions for their effects on vaccine intentions and uptake as well as their precursors, such as knowledge, attitudes, knowledge and none on emotions (Hakim et al. 2018).
The purpose of this study is to evaluate the effects of visualization conveying the concept of community immunity on risk perception (to individual, family, community and vulnerable people in communities) (primary outcome) and on emotions, attitudes, knowledge, and behavioural intentions (secondary outcomes).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 5516
- Members of the general population in Canada
- At least 18 years old
- Able to provide free and informed consent
- Able to read and understand French or English
- Able to use a computer
- No internet access
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Arm && Interventions
Group Intervention Description guardianmeasles guardianmeasles Video (comparator) provided. Participant answers outcome questions about measles. English only. herdimmgeneric herdimm Web-based application (main intervention) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English and French. herdimmmeasles herdimm Web-based application (main intervention) provided. Participant answers outcome questions about measles. English and French. herdimmpertussis herdimm Web-based application (main intervention) provided. Participant answers outcome questions about pertussis. English and French. herdimmflu herdimm Web-based application (main intervention) provided. Participant answers outcome questions about flu. English and French. robertkochgeneric robertkochgeneric Web-based application (comparator) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English only. sbsnewsgeneric sbsnewsgeneric Video (comparator) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English only. theotheredmundmeasles theotheredmundmeasles Video (comparator) provided. Participant answers outcome questions about measles. English only. publichealthagencycanadaflu publichealthagencycanadaflu Video (comparator) provided. Participant answers outcome questions about flu. English and French.
- Primary Outcome Measures
Name Time Method Risk perception immediately after intervention or control 6 items assessing risk perception (item 1 = risk perception as comprehension, scale 0-100, higher numbers better; items 2-5 = risk perception as feelings, scale 1-7, higher numbers better; complete list of items and response wording available in uploaded questionnaire herdimm_phase3_questionnaire_2021-03-01.pdf)
- Secondary Outcome Measures
Name Time Method Knowledge immediately after intervention or control 15 items, with 2 multiple choice questions and 13 true/false questions, for a total possible score ranging from 0 to 18; higher numbers better; complete list of items available in uploaded questionnaire herdimm_phase3_questionnaire_2021-03-01.pdf
Trust in information immediately after intervention or control Single item (Control: "During your life, you may have seen information about vaccines. Thinking about the information you have seen, how trustworthy was it?" Treatment: "Earlier, you saw a {{video, website}} about herd immunity. Thinking about the {{video, website}} you saw earlier, how trustworthy was the information in it?") with Likert-type response options 1 = not at all trustworthy, 2 = moderately untrustworthy, 3 = slightly untrustworthy, 4 = neutral, 5 = slightly trustworthy, 6 = moderately trustworthy, 7 = strongly trustworthy
Vaccination intentions immediately after intervention or control Questions conditioned on whether the participant indicates they believe they are already immune to the disease in question, e.g., "Imagine you were not already immune to {{measles/pertussis/influenza/a vaccine preventable disease}}. If you were eligible to receive a free vaccine against {{measles/pertussis/influenza/a vaccine-preventable disease}}, how likely would you be to get vaccinated?" Response scale on a slider: 0 = extremely unlikely, I would definitely NOT be vaccinated; 100 = extremely likely, I would definitely BE vaccinated; higher numbers better.
5C scale immediately after intervention or control "5C scale: 15-item validated scale measuring the psychological antecedents of vaccination (Betsch et al., 2018)"
Emotions immediately after intervention or control 5 items (e.g., "I am worried about getting \[disease\]", "I would feel guilty if a vulnerable person (a baby, a young child, an older person, a cancer patient) got \[disease\] from me") with a 7-point Likert-type response scale ranging from "strongly disagree" to "strongly agree"; higher numbers may be better; complete list of items and response wording available in uploaded questionnaire herdimm_phase3_questionnaire_2021-03-01.pdf
Trial Locations
- Locations (1)
UniversitƩ Laval
šØš¦QuĆ©bec, Canada